Sigbjørn Smeland

• Slørdahl, Kathinka Schmidt; Puco, Katarina; Falk, Ragnhild Sørum; Dyvik, Ingrid; Brabrand, Sigmund & Niehusmann, Pitt [Vis alle 19 forfattere av denne artikkelen] (2026). Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial. Acta Oncologica. ISSN 0284-186X. 65, s. 90–96. doi: 10.2340/1651-226X.2026.45086. Fulltekst i vitenarkiv Vis sammendrag

  Background and purpose: Molecular profiling guides cancer treatment, by identifying actionable genomic alterations. The IMPRESS-Norway trial (NCT04817956) is a nation-wide precision medicine trial evaluating the efficacy of approved cancer drugs on a novel indication in patients with advanced cancers harbouring potentially actionable alterations. Trametinib, a selective MEK1/2 inhibitor targeting the Mitogen-Activated Protein Kinase (MAPK) signalling pathway, is approved for BRAF V600 mutant melanoma but may also show activity in tumours with other alterations. This sub-study aimed to assess the efficacy of trametinib monotherapy across tumour types with alterations activating the MAPK signalling pathway. Patient/material and methods: In the IMPRESS-Norway trial patients are screened with the TruSight Oncology 500 panel or circulating tumour DNA profiling. Eligible patients are offered biomarker matched targeted therapies. In this subgroup analysis, we identified patients treated with trametinib monotherapy. Primary endpoints were disease control rate (DCR) after 16 weeks and safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Results: DCR after 16 weeks of treatment was 39% in 52 response evaluable patients, with four patients (8%) experiencing partial response, and 16 (31%) stable disease. Responses were seen in tumours harbouring BRAF fusions, GNA11, GNAQ, KRAS, NF1, and NRAS alterations, most frequently in low-grade serous ovarian cancer, central nervous system tumours, and uveal melanoma. Forty-eight percent of patients experienced treatment-related adverse events, including two treatment related deaths. Median PFS and OS were 4 and 9 months, respectively. Interpretation: Trametinib monotherapy achieved a 39% DCR in patients lacking standard options, supporting further studies to confirm efficacy and identify predictive biomarkers for treatment response.

• Nordengen, Anne Lene; Krutto, Annika; Kværner, Ane Sørlie; Alavi, Dena Treider; Henriksen, Hege Berg & Kolle, Åshild [Vis alle 13 forfattere av denne artikkelen] (2025). Plant-based diet and oxidative stress-induced DNA damage in post-surgery colorectal cancer patients: Results from a randomized controlled trial. Free Radical Biology & Medicine. ISSN 0891-5849. 233, s. 240–249. doi: 10.1016/j.freeradbiomed.2025.03.047. Fulltekst i vitenarkiv Vis sammendrag

  Oxidative stress-induced DNA damage may impact long-term outcomes in colorectal cancer (CRC) patients. While bioactive compounds in plant foods have been linked to DNA protection, evidence among patients in remission remains limited. The present study aimed to investigate the effect of a one-year personalized intensive dietary intervention on DNA damage in post-surgery, non-metastatic CRC patients. Participants were enrolled 2–9 months after surgery in the ongoing randomized controlled trial, Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET). Eligible participants (aged 50–80 years, primary stage I-III CRC) were randomized to either a plant-based dietary intervention targeting oxidative stress and inflammation, or to a control group that received standard dietary advice as a part of routine cancer care. As a secondary analysis, this study included 156 participants (78 in the intervention group and 78 in the control group) from the total 503 patients enrolled in CRC-NORDIET study. DNA damage in peripheral mononuclear blood cells (PBMCs) was assessed using the enzyme-modified comet assay during a 12-month follow-up period. A significant intervention effect on DNA base oxidation from baseline to 12 months was observed (P = 0.04), representing a 32 % reduction in the intervention group compared to the control group. No significant effect on DNA strand breaks was found. In conclusion, adherence to a plant-based dietary pattern may reduce DNA base oxidation in post-surgery CRC patients.

• Nordengen, Anne Lene; Krutto, Annika; Kværner, Ane Sørlie; Alavi, Dena Treider; Henriksen, Hege & Smeland, Sigbjørn [Vis alle 11 forfattere av denne artikkelen] (2024). Attenuation of DNA base oxidation in post-surgery colorectal stage III patients at subsequent follow-ups. Free Radical Biology & Medicine. ISSN 0891-5849. 221, s. 75–80. doi: 10.1016/j.freeradbiomed.2024.05.029. Fulltekst i vitenarkiv Vis sammendrag

  DNA damage caused by oxidative reactions plays a crucial role in the pathogenesis of colorectal cancer (CRC). In a previous cross-sectional study, CRC patients diagnosed with regional disease (stage III) exhibited a higher level of DNA base oxidation in peripheral blood mononuclear cells (PBMCs) 2–9 months post-surgery compared to those with localized disease (stage I-II). To further explore this observation over time, the present study aimed to investigate DNA base oxidation in CRC patients with localized versus regional disease 6 and 12 months after the initial measurements. The present study included patients enrolled in the randomized controlled trial Norwegian Dietary Guidelines and Colorectal Cancer Survival (CRC-NORDIET). The standard comet assay, modified with the lesion-specific enzyme formamidopyrimidine DNA glycosylase (Fpg), was applied to measure DNA base oxidation in PBMCs at the 6- and 12-month follow-ups. Of the 255 patients assessed at baseline, 156 were included at the 6-month follow-up, with 89 of these patients included in the 12-month follow-up. In contrast to our observation at baseline, there were no significant differences in the levels of DNA base oxidation between patients diagnosed with localized disease and those with regional involvement at the 6- and 12-month follow-up visits (P = 0.81 and P = 0.09, respectively). Patients with stage III disease exhibited a significant decrease in the levels of DNA base oxidation from baseline to 6 months (P < 0.01) and baseline to 12 months (P = 0.03), but no significant difference from 6 to 12 months (P = 0.80). In conclusion, the initially elevated levels of DNA base oxidation in PBMCs, observed 2–9 months post-surgery in patients diagnosed with regional disease (stage III), subsequently decreased to levels comparable to patients with localized disease (stage I-II) at the 6- and 12-month follow-ups.

• Schlander, Michael; Harten, Wim van; Retèl, Valesca P; Pham, Phu Duy; Vancoppenolle, Julie M & Ubels, Jasper [Vis alle 25 forfattere av denne artikkelen] (2024). The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions. The Lancet Oncology. ISSN 1470-2045. 25(4), s. 152–163. doi: 10.1016/S1470-2045(23)00636-8. Fulltekst i vitenarkiv
• Nordengen, Anne Lene; Zheng, Congying; Krutto, Annika; Kværner, Ane Sørlie; Alavi, Dena Treider & Henriksen, Hege [Vis alle 13 forfattere av denne artikkelen] (2024). Effect of a personalized intensive dietary intervention on base excision repair (BER) in colorectal cancer patients: Results from a randomized controlled trial. Free Radical Biology & Medicine. ISSN 0891-5849. 218, s. 178–189. doi: 10.1016/j.freeradbiomed.2024.04.211. Fulltekst i vitenarkiv Vis sammendrag

  DNA repair is essential to maintain genomic integrity and may affect colorectal cancer (CRC) patients’ risk of secondary cancers, treatment efficiency, and susceptibility to various comorbidities. Bioactive compounds identified in plant food have the potential to modulate DNA repair mechanisms, but there is limited evidence of how dietary factors may affect DNA repair activity in CRC patients in remission after surgery. The aim of this study was to investigate the effect of a 6 months personalized intensive dietary intervention on DNA repair activity in post-surgery CRC patients (stage I-III). The present study included patients from the randomized controlled trial CRC-NORDIET, enrolled 2-9 months after surgery. The intervention group received an intensive dietary intervention emphasizing a prudent diet with specific plant-based foods suggested to dampen inflammation and oxidative stress, while the control group received only standard care advice. The comet-based in vitro repair assay was applied to assess DNA repair activity, specifically base excision repair (BER), in peripheral blood mononuclear cells (PBMCs). Statistical analyses were conducted using gamma generalized linear mixed models (Gamma GLMM). A total of 138 CRC patients were included, 72 from the intervention group and 66 from the control group. The BER activity in the intervention group did not change significantly compared to the control group. Our findings revealed a substantial range in both inter- and intra-individual levels of BER. In conclusion, the results do not support an effect of dietary intervention on BER activity in post-surgery CRC patients during a 6-month intervention period.

• Puco, Katarina; Fagereng, Gro Live; Brabrand, Sigmund; Niehusmann, Pitt; Blix, Egil Støre & Steinskog, Eli Sihn Samdal [Vis alle 24 forfattere av denne artikkelen] (2024). IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncologica. ISSN 0284-186X. 63, s. 379–384. doi: 10.2340/1651-226X.2024.28322. Fulltekst i vitenarkiv
• Palmerini, Emanuela; Reichardt, Peter; Hall, Kirsten Sundby; Bertulli, Rossella; Bielack, Stefan S. & Comandone, Alessandro [Vis alle 18 forfattere av denne artikkelen] (2023). Outcome of rare primary malignant bone sarcoma (RPMBS) treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S). Cancer. ISSN 0008-543X. doi: 10.1002/cncr.34964. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Background Rare primary malignant bone sarcomas (RPMBS) account for 5%–10% of primary high‐grade bone tumors and represent a major treatment challenge. The outcome of patients with RPMBS enrolled in the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S) is presented. Methods Inclusion criteria were as follows: age from 41 to 65 years and a diagnosis of high‐grade spindle cell, pleomorphic, or vascular RPMBS. The chemotherapy regimen included doxorubicin 60 mg/m 2 , ifosfamide 9 g/m 2 , and cisplatin 90 mg/m 2 ; postoperative methotrexate 8 g/m 2 was added in case of a poor histologic response. Version 2.0 of the Common Terminology Criteria for Adverse Events, Kaplan–Meier curves, log‐rank tests, and univariate Cox regression models were used. Results In total, 113 patients were evaluable for analysis. The median patient age was 52 years (range, 40–66 years), and 67 patients were men. Eighty‐eight tumors were categorized as undifferentiated pleomorphic sarcomas (UPS), 20 were categorized as leiomyosarcomas, three were categorized as fibrosarcomas, and two were categorized as angiosarcomas. Eighty‐three of 113 tumors were located in the extremities. Ninety‐five of 113 patients presented with no evidence of metastases. After a median follow‐up of 6.8 years (interquartile range [IQR], 3.5–9.8 years), the 5‐year overall survival rate for patients with localized disease was 68.4% (IQR, 56.9%–77.5%), and it was 71.7% (IQR, 58.1%–81.6%) for patients with UPS and 54.9% (IQR, 29.5%–74.5%) for patients with leiomyosarcoma. Grade III–IV hematologic toxicity was reported in 81% patients; 23% had grade II–III neurotoxicity, and 37.5% had grade I–II nephrotoxicity. Five‐year overall survival was significantly better for patients with localized disease, for patients who obtained surgical complete remission, and when the primary tumor was located in the extremities. Conclusions The survival of patients who had RPMBS in the current series was similar to that of age‐matched patients who had high‐grade osteosarcoma treated according to the same protocol. An osteosarcoma‐like chemotherapy may be proposed in patients who have RPMBS.

• Nordengen, Anne Lene; Kværner, Ane Sørlie; Krutto, Annika; Alavi, Dena Treider; Henriksen, Hege & Henriksen, Christine [Vis alle 12 forfattere av denne artikkelen] (2023). DNA base oxidation in relation to TNM stages and chemotherapy treatment in colorectal cancer patients 2–9 months post-surgery. Free Radical Biology & Medicine. ISSN 0891-5849. 212, s. 174–185. doi: 10.1016/j.freeradbiomed.2023.12.016. Fulltekst i vitenarkiv Vis sammendrag

  Accumulation of DNA damage is a critical feature of genomic instability, which is a hallmark of various cancers. The enzyme-modified comet assay is a recognized method to detect specific DNA lesions at the level of individual cells. In this cross-sectional investigation, we explore possible links between clinicopathological and treatment related factors, nutritional status, physical activity and function, and DNA damage in a cohort of colorectal cancer (CRC) patients with non-metastatic disease. Levels of DNA damage in peripheral mononuclear blood cells (PBMCs) assessed 2–9 months post-surgery, were compared across tumour stage (localized (stage I-II) vs. regional (stage III) disease), localization (colon vs. rectosigmoid/rectum cancer), and adjuvant chemotherapy usage, with the last dosage administrated 2–191 days prior to sampling. Associations between DNA damage and indicators of nutritional status, physical activity and function were also explored. In PBMCs, DNA base oxidation was higher in patients diagnosed with regional compared with localized tumours (P = 0.03), but no difference was seen for DNA strand breaks (P > 0.05). Number of days since last chemotherapy dosage was negatively associated with DNA base oxidation (P ＜ 0.05). In conclusion, DNA base oxidation measured with the enzyme-modified comet assay varies according to tumour and lifestyle related factors in CRC patients treated for non-metastatic disease.

• Høland, Maren; Berg, Kaja Christine Graue; Eilertsen, Ina Andrassy; Bjerkehagen, Bodil; Kolberg, Matthias & Pedersen, Kjetil Boye [Vis alle 16 forfattere av denne artikkelen] (2023). Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets. EBioMedicine. 97:104829, s. 1–17. doi: 10.1016/j.ebiom.2023.104829. Fulltekst i vitenarkiv Vis sammendrag

  Background Malignant peripheral nerve sheath tumour (MPNST) is an aggressive orphan disease commonly affecting adolescents or young adults. Current knowledge of molecular tumour biology has been insufficient for development of rational treatment strategies. We aimed to discover molecular subtypes of potential clinical relevance. Methods Fresh frozen samples of MPNSTs (n = 94) and benign neurofibromas (n = 28) from 115 patients in a European multicentre study were analysed by DNA copy number and/or transcriptomic profiling. Unsupervised transcriptomic subtyping was performed and the subtypes characterized for genomic aberrations, clinicopathological associations and patient survival. Findings MPNSTs were classified into two transcriptomic subtypes defined primarily by immune signatures and proliferative processes. “Immune active” MPNSTs (44%) had sustained immune signals relative to neurofibromas, were more frequently low-grade (P = 0.01) and had favourable prognostic associations in a multivariable model of disease-specific survival with clinicopathological factors (hazard ratio 0.25, P = 0.003). “Immune deficient” MPNSTs were more aggressive and characterized by proliferative signatures, high genomic complexity, aberrant TP53 and PRC2 loss, as well as high relative expression of several potential actionable targets (EGFR, ERBB2, EZH2, KIF11, PLK1, RRM2). Integrated gene-wise analyses suggested a DNA copy number-basis for proliferative transcriptomic signatures in particular, and the tumour copy number burden further stratified the transcriptomic subtypes according to patient prognosis (P < 0.01). Interpretation Approximately half of MPNSTs belong to an “immune deficient” transcriptomic subtype associated with an aggressive disease course, PRC2 loss and expression of several potential therapeutic targets, providing a rationale for molecularly-guided intervention trials.

• Skaali, Tone Margrethe Olsbu; Blomhoff, Rune; Lindemann, Kristina Yvonne Kathe; Smeland, Sigbjørn; Bruheim, Kjersti & Selland, Mette [Vis alle 7 forfattere av denne artikkelen] (2023). Self-reported distress and problems after treatment for gynecological cancer – Correlation between a short screening tool and longer measures of anxiety/depression and health-related quality of life. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. doi: 10.1111/aogs.14709. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Introduction The National Comprehensive Cancer Network (NCCN) distress thermometer and problem list (DTPL) is a brief self‐report screening measure for use in follow‐up cancer care. The aims of this study were to explore the correlations between scores on the DTPL and scores on longer measures of anxiety/depression and health‐related quality of life among women treated for gynecological cancer, and to define a cutoff score on the DT representing high levels of psychological distress in this patient group. Material and methods During outpatient visits, 144 women filled in the DTPL, the Hospital Anxiety and Depression Scale (HADS) and the RAND‐36‐Item Short Form Health Survey (RAND‐36) between October 2019 and March 2020. We assessed the agreement between the DT‐scores and the HADS scores, explored variables associated with high levels of distress on the DT, and studied the associations between DTPL‐scores and scores of health‐related quality of life (HRQoL) from RAND‐36. Results In receiver operating characteristic curve analysis between the distress score from the DT and a HADS total score ≥15 (defining high levels of anxiety/depression symptoms), the area under the curve was 0.81 (95% CI: 0.74–0.89). Using a cutoff of ≥5 on the DT (scale 0–10), we found a balanced level of sensitivity (81%) and specificity (71%) towards a HADS total score of ≥15. The scores of distress and problems reported on the DTPL correlated significantly with the majority of HRQoL function scales from RAND‐36. Conclusions The NCCN DTPL can be used as a screening measure for self‐reported distress and problems after treatment for gynecological cancer. A score of ≥5 on DT may indicate high level of anxiety/depression as measured by HADS. The tool may help identify patients in need of referral to supportive care and rehabilitation facilities.

• Alavi, Dena Treider; Henriksen, Hege Berg; Lauritzen, Peter Mæhre; Zucknick, Manuela; Bøhn, Siv Kjølsrud & Henriksen, Christine [Vis alle 9 forfattere av denne artikkelen] (2023). Effect of a one-year personalized intensive dietary intervention on body composition in colorectal cancer patients: Results from a randomized controlled trial. Clinical Nutrition ESPEN. ISSN 2405-4577. 57, s. 414–422. doi: 10.1016/j.clnesp.2023.06.037. Fulltekst i vitenarkiv Vis sammendrag

  Background & aims Changes in body composition may affect colorectal cancer (CRC) patient's risk of cancer recurrence, secondary cancer, and other chronic diseases. The suggested interventions for changes in body composition such as low muscle mass or high fat mass, are diet and physical activity. Nevertheless, there is limited evidence of how dietary intervention alone can impact body composition. This study aimed to investigate the effect of a 6 and 12 month dietary intervention with a focus on healthy eating according to Norwegian food-based dietary guidelines on weight and body composition in patients with CRC stage I-III, post-surgery.<p> <p>Methods This study included participants from the randomized controlled trial CRC-NORDIET study 2–9 months after surgery. The intervention group received an intensive dietary intervention, while the control group underwent similar measurements, but no dietary intervention. Body composition was measured with Lunar iDXA, and the results were analyzed using linear mixed models. <p>Results A total of 383 participants were included, 192 in the intervention group and 191 in the control group. After 6 months, the intervention group showed a 0.7 kg lower mean weight gain (p = 0.020) and 0.6 kg lower fat mass gain (p = 0.019) than the control group, but no difference at 12 months. Moreover, the fat mass increase was 0.5 percentage points lower at 6 months (p = 0.012), and 0.7 percentage points lower at 12 months (p = 0.011) in the intervention group compared to the controls. At 6 months, the intervention group had 63 g lower gain of visceral adipose tissue compared to the control group (p = 0.031). No differences were seen for fat-free mass or subcutaneous adipose tissue at any time point. The intervention group showed a lower increase in the ratio between fat mass and fat-free mass at both 6 months (p = 0.025) and 12 months (p = 0.021). <p>Conclusion The dietary intervention reduced the increases in total weight and fat masses, without changing fat-free mass. Although the individual changes are small, the dietary intervention may have resulted in an overall more favourable body composition profile. These findings suggest that dietary intervention may be part of a treatment strategy for prevention of weight and fat mass gain in CRC survivors.

• Kværner, Ane Sørlie; Andersen, Astrid Riseth; Henriksen, Hege Berg; Knudsen, Markus Dines; Johansen, Anne Marte Wetting & Hjartåker, Anette [Vis alle 13 forfattere av denne artikkelen] (2023). Associations of the 2018 World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) cancer prevention recommendations with stages of colorectal carcinogenesis. Cancer Medicine. 12(13), s. 14806–14819. doi: 10.1002/cam4.6119. Fulltekst i vitenarkiv Vis sammendrag

  Background: While adherence to cancer prevention recommendations is linked to lower risk of colorectal cancer (CRC), few have studied associations across the entire spectrum of colorectal carcinogenesis. Here, we studied the relationship of the standardized 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Score for cancer prevention recommendations with detection of colorectal lesions in a screening setting. As a secondary objective, we examined to what extent the recommendations were being followed in an external cohort of CRC patients. Methods: Adherence to the seven-point 2018 WCRF/AICR Score was measured in screening participants receiving a positive fecal immunochemical test and in CRC patients participating in an intervention study. Dietary intake, body fatness and physical activity were assessed using self-administered questionnaires. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for screen-detected lesions. Results: Of 1486 screening participants, 548 were free from adenomas, 524 had non-advanced adenomas, 349 had advanced lesions and 65 had CRC. Adherence to the 2018 WCRF/AICR Score was inversely associated with advanced lesions; OR 0.82 (95% CI 0.71, 0.94) per score point, but not with CRC. Of the seven individual components included in the score, alcohol, and BMI seemed to be the most influential. Of the 430 CRC patients included in the external cohort, the greatest potential for lifestyle improvement was seen for the recommendations concerning alcohol and red and processed meat, where 10% and 2% fully adhered, respectively. Conclusions: Adherence to the 2018 WCRF/AICR Score was associated with lower probability of screen-detected advanced precancerous lesions, but not CRC. Although some components of the score seemed to be more influential than others (i.e., alcohol and BMI), taking a holistic approach to cancer prevention is likely the best way to prevent the occurrence of precancerous colorectal lesions.

• Budde, Axel; Baust, Katja; Weinhold, Leonie; Bernstein, Mark; Bielack, Stefan & Dhooge, Catharina [Vis alle 19 forfattere av denne artikkelen] (2022). Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma. European Journal of Cancer. ISSN 0959-8049. 170, s. 209–235. doi: 10.1016/j.ejca.2022.03.018. Fulltekst i vitenarkiv Vis sammendrag

  Purpose The available questionnaires for quality-of-life (QoL) assessments are age-group specific, limiting comparability and impeding longitudinal analyses. The comparability of measurements, however, is a necessary condition for gaining scientific evidence. To overcome this problem, we assessed the viability of harmonising data from paediatric and adult patient-reported outcome (PRO) measures. Method To this end, we linked physical functioning scores from the Paediatric Quality of Life Inventory (PedsQL) and the Paediatric Quality of Life Questionnaire (PEDQOL) to the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) for adults. Samples from the EURAMOS-1 QoL sub-study of 75 (PedsQL) and 112 (PEDQOL) adolescent osteosarcoma patients were concurrently administered both paediatric and adult questionnaires on 98 (PedsQL) and 156 (PEDQOL) occasions. We identified corresponding scores using the single-group equipercentile linking method. Results Linked physical functioning scores showed sufficient concordance to the EORTC QLQ-C30: Lin's ρ = 0.74 (PedsQL) and Lin's ρ = 0.64 (PEDQOL). Conclusion Score linking provides clinicians and researchers with a common metric for assessing QoL with PRO measures across the entire lifespan of patients.

• Monsen, Kari Vatne; Fosså, Sophie Dorothea; Myklebust, Tor Åge; Smeland, Sigbjørn; Dahl, Alv A & Stensvold, Andreas (2022). Long-term satisfaction with curative treatment and follow-up in prostate cancer survivors. Acta Oncologica. ISSN 0284-186X. 61(3), s. 357–362. doi: 10.1080/0284186X.2021.2006775. Fulltekst i vitenarkiv Vis sammendrag

  PURPOSE In a cross-sectional observational study to explore long-term satisfaction with treatment among men who had undergone radical prostatectomy (RP) or definitive pelvic radiotherapy (RT) for prostate cancer (PCa). METHODS After mean 7 years from therapy (range: 6–8), 431 PCa-survivors (RP: n = 313, RT: n = 118) completed a mailed questionnaire assessing persistent treatment-related adverse effects (AEs) (Expanded Prostate cancer Index Composite [EPIC-26]) and seven Quality indicators describing satisfaction with the health care service following a most often general practitioner (GP)-led follow-up plan. A logistic regression model evaluated the associations between long-term satisfaction and treatment modality, age, the seven satisfaction-related Quality indicators, and persistent AEs. The significance level was set at p< .05. RESULTS Four of five (81%) PCa-survivors reported long-term satisfaction with their treatment. In a multivariable model, satisfaction was positively associated with sufficient information about treatment and AEs, patient-perceived sufficient cooperation between the hospital and the GP and sufficient follow-up of AEs (ref.: insufficient). Age ≥70 years (ref.: <70) and a rising summary score within the EPIC-26 sexual domain additionally increased long-term satisfaction. The treatment modality itself (RP versus RT) did not significantly impact on satisfaction. CONCLUSIONS The majority of curatively treated PCa-survivors are satisfied with their treatment more than 5 years after primary therapy. Sufficient information, improved cooperation between the hospital specialists and the responsible GP and optimized follow-up of AEs may further increase long-term satisfaction among prostatectomized and irradiated PCa-survivors.

• Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung & Delic-Sarac, Marina [Vis alle 22 forfattere av denne artikkelen] (2022). Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology. ISSN 0007-1048. 197(6), s. 697–708. doi: 10.1111/bjh.18149. Fulltekst i vitenarkiv Vis sammendrag

  B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.

• Mæhle, Per Magnus; Hanto, Ingrid Kristine Small; Simensen, Victoria C & Smeland, Sigbjørn (2021). Mind the differences: How diagnoses and hospital characteristics influence coordination in cancer patient pathways. International Journal of Environmental Research and Public Health (IJERPH). ISSN 1661-7827. 18(16), s. 1–26. doi: 10.3390/ijerph18168818. Fulltekst i vitenarkiv Vis sammendrag

  Integrated care pathway (ICP) is a prevailing concept in health care management including cancer care. Though substantial research has been conducted on ICPs knowledge is still deficient explaining how characteristics of diagnose, applied procedures, patient group and organizational context influence specific practicing of ICPs. We studied how coordination takes place in three cancer pathways in four Norwegian hospitals. We identified how core contextual variables of cancer pathways affect complexity and predictability of the performance of each pathway. Thus, we also point at differences in core preconditions for accomplishing coordination of the cancer pathways. In addition, the findings show that three different types of coordination dynamics are present in all three pathways to a divergent degree: programmed chains, consultative hubs and problem-solving webs. Pathway coordination also depends on hierarchical interaction. Lack of corresponding roles in the medical–professional and the administrative–institutional logics presents a challenge for coordination, both within and between hospitals. We recommend that further improvement of specific ICPs by paying attention to what should be standardized and what should be kept flexible, aligning semi-formal and formal structures to pathway processes and identify the professional cancer related background and management style required by the key-roles in pathway management.

• Hompland, Ivar; Ferrari, Stefano; Bielack, Stefan; Palmerini, Emanuela; Hall, Kirsten Sundby & Picci, Pierro [Vis alle 35 forfattere av denne artikkelen] (2021). Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. European Journal of Cancer. ISSN 0959-8049. 151, s. 150–158. doi: 10.1016/j.ejca.2021.04.017. Fulltekst i vitenarkiv
• Mæhle, Per Magnus; Hajdarevic, Senada; Håland, Erna; Aarhus, Rikke; Smeland, Sigbjørn & Mørk, Bjørn Erik (2021). Exploring the triggering process of a cancer care reform in three Scandinavian countries. International Journal of Health Planning and Management. ISSN 0749-6753. 36(6), s. 2231–2247. doi: 10.1002/hpm.3278. Fulltekst i vitenarkiv Vis sammendrag

  Cancer incidence is increasing, and cancer is a leading cause of death in the Scandinavian countries, and at the same time more efficient but very expensive new treatment options are available. Based on the increasing demand, high expectations and limited resources, crises in public legitimacy of cancer care evolved in the three Scandinavian countries. Similar cancer care reforms were introduced in the period 2007–2015 to address the crisis. In this article we explore processes triggering these reforms in countries with similar and well-developed health care systems. The common objective was the need to reduce time from referral to start treatment, and the tool introduced to accomplish this was integrated care pathways for cancer diagnosis, that is Cancer Patient Pathways. This study investigates the process by drawing on interviews with key actors and public documents. We identified three main logics in play; the economic-administrative, the medical and the patient-related logic and explored how institutional entrepreneurs skillfully aligned these logics. The article contributes by describing the triggering processes on politically initiated similar reforms in the three countries studied and also contributes to a better understanding on the orchestrating of politically initiated health care reforms with the intention to change medical practice in hospitals.

• Johannessen, Tom Børge; Smeland, Sigbjørn; Aaserud, Stein; Buanes, Eirik Alnes; Skog, Anna & Ursin, Giske [Vis alle 7 forfattere av denne artikkelen] (2021). COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway. Frontiers in Oncology. 11. doi: 10.3389/fonc.2021.652535. Fulltekst i vitenarkiv Vis sammendrag

  Background Cancer has been suggested as a risk factor for severe outcome of SARS-CoV-2 infection. In this population-based study we aimed to identify factors associated with higher risk of COVID-19 and adverse outcome. Methods Data on all confirmed SARS-CoV-2 positive patients in the period January 1 to May 31, 2020 were extracted from the Norwegian Surveillance System for Communicable Diseases. Data on cancer and treatment was available from the Cancer Registry of Norway, the Norwegian Patient Registry and the Norwegian Prescription Database. Deaths due to COVID-19 were extracted from the Cause of Death Registry. From the Norwegian Intensive Care and Pandemic Registry we retrieved data on admittance to hospital and intensive care. We determined rates of COVID-19 disease in cancer patients and the rest of the population. We also ran multivariate analyses adjusting for age and gender. Results A total of 8 410 patients were diagnosed with SARS-CoV-2 infection in Norway during the study period, of which 547 (6.5%) were cancer patients. Overall, we found similar age adjusted rates of COVID-19 in the population with cancer as in the population without cancer. Unadjusted analysis showed that patients having undergone major surgery within the past 3 months had an increased risk of COVID-19 while we did not find increased Odds Ratio (OR) related to other oncological treatment modalities. No patients treated with stem cell or bone marrow transplant were diagnosed with COVID-19. The fatality rate of COVID-19 among cancer patients was 0.10. This was similar to non-cancer patients, when adjusting for age and sex with OR (95% CI) for death= 0.99 (0.68–1.42). Patients with distant metastases had significantly increased OR of death due to COVID-19 disease of 9.31 (95% CI 2.60–33.34). For the combined outcome death and/or admittance to hospital due to COVID-19, we found significant two-fold increased risk estimates for patients diagnosed with cancer less than one 1 year ago (OR 2.08, 95% CI 1.14–3.80), for those treated with anti-cancer drugs during the past 3 months (OR 1.80, 95% CI 1.07–3.01) and for patients undergoing major surgery during the past 3 months (OR 2.19, 95% CI 1.40–3.44).

• Mæhle, Per Magnus & Smeland, Sigbjørn (2021). Implementing cancer patient pathways in Scandinavia how structuring might affect the acceptance of a politically imposed reform. Health Policy. ISSN 0168-8510. doi: 10.1016/j.healthpol.2021.08.008. Fulltekst i vitenarkiv
• Alavi, Dena Helene; Henriksen, Hege; Lauritzen, Peter Mæhre; Kværner, Ane Sørlie; Sakinis, Tomas & Langleite, Torgrim Mikal [Vis alle 12 forfattere av denne artikkelen] (2021). Quantification of adipose tissues by Dual-Energy X-Ray Absorptiometry and Computed Tomography in colorectal cancer patients. Clinical Nutrition ESPEN. ISSN 2405-4577. 43, s. 360–368. doi: 10.1016/j.clnesp.2021.03.022. Fulltekst i vitenarkiv Vis sammendrag

  Background & aims Excess adipose tissue may affect colorectal cancer (CRC) patients' disease progression and treatment. In contrast to the commonly used anthropometric measurements, Dual-Energy X-Ray Absorptiometry (DXA) and Computed Tomography (CT) can differentiate adipose tissues. However, these modalities are rarely used in the clinic despite providing high-quality estimates. This study aimed to compare DXA's measurement of abdominal visceral adipose tissue (VAT) and fat mass (FM) against a corresponding volume by CT in a CRC population. Secondly, we aimed to identify the best single lumbar CT slice for abdominal VAT. Lastly, we investigated the associations between anthropometric measurements and VAT estimated by DXA and CT. Methods Non-metastatic CRC patients between 50-80 years from the ongoing randomized controlled trial CRC-NORDIET were included in this cross-sectional study. Corresponding abdominal volumes were acquired by Lunar iDXA and from clinically acquired CT examinations. Also, single CT slices at L2-, L3-and L4-level were obtained. Agreement between the methods was investigated using univariate linear regression and Bland–Altman plots. Results Sixty-six CRC patients were included. Abdominal volumetric VAT and FM measured by DXA explained up to 91% and 96% of the variance in VAT and FM by CT, respectively. Bland–Altman plots demonstrated an overestimation of VAT by DXA compared to CT (mean difference of 76 cm3) concurrent with an underestimation of FM (mean difference of −319 cm3). A higher overestimation of VAT (p = 0.015) and underestimation of FM (p = 0.036) were observed in obese relative to normal weight subjects. VAT in a single slice at L3-level showed the highest explained variance against CT volume (R2 = 0.97), but a combination of three slices (L2, L3, L4) explained a significantly higher variance than L3 alone (R2 = 0.98, p < 0.006). The anthropometric measurements explained between 31-65% of the variance of volumetric VAT measured by DXA and CT. Conclusions DXA and the combined use of three CT slices (L2-L4) are valid to predict abdominal volumetric VAT and FM in CRC patients when using volumetric CT as a reference method. Due to the poor performance of anthropometric measurements we recommend exploring the added value of advanced body composition by DXA and CT integrated into CRC care.

• Bärebring, Linnea; Kværner, Ane Sørlie; Skotnes, Madeleine; Henriksen, Hege; Skjetne, Anne Juul & Henriksen, Christine [Vis alle 12 forfattere av denne artikkelen] (2020). Use of bioelectrical impedance analysis to monitor changes in fat-free mass during recovery from colorectal cancer– a validation study. Clinical Nutrition ESPEN. ISSN 2405-4577. 40, s. 201–207. doi: 10.1016/j.clnesp.2020.09.021. Fulltekst i vitenarkiv Vis sammendrag

  Background & aims Although previous research show high correlation between fat-free mass (FFM) measured by bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA), the validity of BIA to track longitudinal changes in FFM is uncertain. Thus, the aim of this study was to validate the ability of BIA to assess changes in FFM during 6 months of recovery from non-metastatic colorectal cancer (CRC). Methods A total of 136 women and men (50–80 years) with stage I-III CRC and a wide range of baseline FFM (35.7–73.5 kg) were included in the study. Body composition was measured at study baseline within 2–9 months of surgery and again 6 months later. Whole-body BIA FFM estimates (FFMBIA) were calculated using three different equations (manufacturer's, Schols' and Gray's) before comparison to FFM estimates obtained by DXA (FFMDXA). Results Correlation between changes in FFMBIA and FFMDXA was intermediate regardless of equation (r ≈ 0.6). The difference in change of FFMBIA was significant compared to FFMDXA, using all three equations and BIA overestimated both loss and gain. However, BIA showed 100% sensitivity and about 90% specificity to identify individuals with ≥5% loss in FFM, using all three equations. Sensitivity of FFMBIA to detect a smaller loss of FFM (60–76%) or a gain in FFM of ≥5% (33–62%) was poor. Conclusion In a well-nourished population of non-metastatic CRC patients, a single-frequency whole-body BIA device yielded imprecise data on changes in FFM, regardless of equation. BIA is thus not a valid option for quantifying changes in FFM in individuals. However, BIA could be used to identify patients with loss in FFM ≥5% in this population. The validity of BIA to monitor changes in FFM warrants further investigation before implementation in clinical praxis.

• Vatne, Kari; Fosså, Sophie Dorothea; Dahl, Alv A; Myklebust, Tor Åge; Smeland, Sigbjørn & Stensvold, Andreas (2020). Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life. Scandinavian Journal of Urology. ISSN 2168-1805. s. 1–8. doi: 10.1080/21681805.2020.1854343. Fulltekst i vitenarkiv Vis sammendrag

  Background Few longitudinal studies have compared patient-reported long-term adverse effects after radical prostatectomy (RP) alone and RP followed by radiotherapy (RAD), also analyzing the effect of the development of post-treatment dysfunctions/problems (Symptom Burden) on Health-Related Quality of Life (HRQoL). Material and methods After median seven years since RP and six years since post-RP RAD, development of EPIC-26 Domain Summary Scores (DSS Changes) and HRQoL scores (SF-12) since the pre-RP situation were evaluated in respectively 317 prostatectomized men without and in 63 patients with additional post-RP RAD. Post-treatment inter-group differences of the prevalent Symptom Burden and of the DSS Changes were calculated. Multivariable logistic regressions evaluated the associations between DSS Changes and post-treatment impaired HRQoL. Results Compared to RP alone, post-RP RAD increased the post-treatment Symptom Burden, with least inter-group differences within the urinary irritative/obstructive and bowel domain. No significant inter-group difference emerged for the proportions of men with impaired HRQoL. The odds of impaired HRQoL increased significantly with rising DSS Changes (worsening) within the vitality/hormonal domain. Worsening within urinary incontinence and bowel domains significantly increased the odds of impaired physical QoL. High HRQoL scores before RP reduced the odds of post-treatment impaired HRQoL. Living without a partner and use of androgen deprivation therapy increased this odds. Conslusions Post-RP radiotherapy increases post-treatment Symptom Burden with negative, though limited impact on the patient’s HRQoL. Counceling before post-RP radiotherapy should cover this possible development, taking into account the patient’s social situation.

• Mæhle, Per Magnus; Hanto, Ingrid Kristine Small & Smeland, Sigbjørn (2020). Practicing integrated care pathways in norwegian hospitals: Coordination through industrialized standardization, value chains, and quality management or an organizational equivalent to improvised jazz standards. International Journal of Environmental Research and Public Health (IJERPH). ISSN 1661-7827. 17(24), s. 1–32. doi: 10.3390/ijerph17249199. Fulltekst i vitenarkiv Vis sammendrag

  The goal of coordinating pathways for cancer patients through their diagnostic and treatment journey is often approached by borrowing strategies from traditional industries, including standardization, process redesign, and variation reduction. However, the usefulness of these strategies is sometimes limited in the face of the complexity and uncertainty that characterize these processes over time and the situation at both patient and institutional levels. We found this to be the case when we did an in-depth qualitative study of coordination processes in patient pathways for three diagnoses in four Norwegian hospitals. What allows these hospitals to accomplish coordination is supplementing standardization with improvisation. This improvisation is embedded in four types of emerging semi-formal structures: collegial communities, networks, boundary spanners, and physical proximity. The hierarchical higher administrative levels appear to have a limited ability to manage and support coordination of these emerging structures when needed. We claim that this can be explained by viewing line management as representative of an economic–administrative institutional logic while these emerging structures represent a medical–professional logic that privileges proximity to the variation and complexity in the situations. The challenge is then to find a way for emergent and formal structures to coexist.

• Kværner, Ane Sørlie; Harnæs, Helene; Alavi, Dena Helene; Bärebring, Linnea; Henriksen, Hege & Guren, Marianne [Vis alle 11 forfattere av denne artikkelen] (2020). Bør beregning av cellegiftdose ved tarmkreft baseres på kroppssammensetning? Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 140(8), s. 1–10. doi: 10.4045/tidsskr.19.0769. Fulltekst i vitenarkiv
• Smeland, Sigbjørn; Bielack, Stefan S.; Whelan, Jeremy; Bernstein, Mark; Hogendoorn, Pancras & Krailo, Mark D. [Vis alle 52 forfattere av denne artikkelen] (2019). Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer. ISSN 0959-8049. 109, s. 36–50. doi: 10.1016/j.ejca.2018.11.027. Fulltekst i vitenarkiv Vis sammendrag

  Background High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by facilitating randomised controlled trials. Methods Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade osteosarcoma in which case complete surgical resection at all sites was deemed to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. We report survival outcomes and prognostic factors in the full cohort of registered patients. Results For all registered patients at a median follow-up of 54 months (interquartile range: 38–73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]: 57–61%) and 54% (95% CI: 52–56%), respectively. Multivariate analyses showed that the most adverse factors at diagnosis were pulmonary metastases (hazard ratio [HR] = 2.34, 95% CI: 1.95–2.81), non-pulmonary metastases (HR = 1.94, 95% CI: 1.38–2.73) or an axial skeleton tumour site (HR = 1.53, 95% CI: 1.10–2.13). The histological subtypes telangiectatic (HR = 0.52, 95% CI: 0.33–0.80) and unspecified conventional (HR = 0.67, 95% CI: 0.52–0.88) were associated with a favourable prognosis compared with chondroblastic subtype. The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77–81%) and 71% (95% CI: 68–73%), respectively. For patients with localised disease at presentation and in complete remission after surgery, having a poor histological response was associated with worse outcome after surgery (HR = 2.13, 95% CI: 1.76–2.58). In radically operated patients, there was no good evidence that axial tumour site was associated with worse outcome. Conclusions In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.

• Jha, Anjani Kumar; Neupane, Pradeep; Pradhan, Manohar; Sharma, Krishna Sagar; Shrestha, Sadina & Sigdel, Padma Raj [Vis alle 8 forfattere av denne artikkelen] (2019). Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy. Journal of Global Oncology (JGO). 2019(5), s. 1–10. doi: 10.1200/JGO.19.00015. Fulltekst i vitenarkiv Vis sammendrag

  To our knowledge, we conducted the first prospective oncologic clinical trial in Nepal aimed at providing state-of-the-art chemotherapy to patients with Ewing sarcoma. The efficacy of external-beam radiotherapy (RT) as the sole local treatment modality was explored and deemed justified as a result of the lack of available advanced tumor-orthopedic services in Nepal. PATIENTS AND METHODS Twenty patients, 11 female and 9 male patients between the ages of 6 and 37 years, with newly diagnosed Ewing sarcoma were enrolled. Neoadjuvant combination chemotherapy, comprising well-established drug combinations, was administered in five courses before external-beam RT, during which one course of etoposide and ifosfamide was given. After RT, six additional chemotherapy courses were scheduled. RT was tolerated well, providing rapid symptom relief and local tumor control, with no pathologic fractures observed among the 15 patients who received such treatment. Eleven patients completed the entire treatment protocol; seven patients were under continued follow-up, with no evidence of disease in six patients at a median follow-up time of 2.3 years (range, 1.3 to 3.1 years) and one patient alive but with a regional recurrence. Four patients experienced metastatic relapse and died as a result of their disease. Three treatment-related deaths linked to toxicity from chemotherapy occurred. Four of the six patients who refused to complete the treatment protocol and were lost to follow-up experienced progressive disease and were assumed dead. This study was feasible with RT as the sole local treatment modality in combination with chemotherapy. As a result of the high number of patients lost to follow-up, no firm conclusions can be drawn, but the majority of the patients who completed treatment obtained durable long-term remissions.

• Henriksen, Hege Berg; Henriksen, Christine; Ræder, Hanna; Kværner, Ane Sørlie; Skjetne, Anne Juul & Bøhn, Siv Kjølsrud [Vis alle 11 forfattere av denne artikkelen] (2019). Hvilke kostråd skal man gi til pasienter behandlet for tarmkreft? Norsk tidsskrift for ernæring (NTFE). ISSN 1503-5034. s. 32–36. Fulltekst i vitenarkiv
• Calaminus, Gabriele; Jenney, Meriel; Hjorth, Lars; Baust, Katja; Bernstein, Mark & Bielack, Stefan S. [Vis alle 21 forfattere av denne artikkelen] (2019). Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. JMIR Research Protocols. doi: 10.2196/14406. Fulltekst i vitenarkiv Vis sammendrag

  The quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand the QoL of patients undergoing treatment for OS to improve the QoL. We report on the first prospective international QoL study that was embedded within a large randomized clinical trial from 4 national study groups. This paper aimed to describe the QoL study development, methodology, accrual details, and characteristics of the QoL cohort. A total of 2260 patients registered in the EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1), of whom 97.92% (2213/2260) were eligible for the optional QoL assessment and could participate in terms of questionnaire availability. Overall, 61.86% (1369/2213) of patients and/or proxies completed the QoL evaluation at the first assessment time point (E1) after the start of preoperative treatment. The QoL measures used (self- and/or proxy reports) depending on the patient’s age and national study group. Participants and nonparticipants in the ancillary QoL study were compared regarding relevant demographic and disease-related characteristics at registration in the trial. The participation rate at time point E1 did not differ with regard to age, gender, the occurrence of pathological fracture, or the presence of any metastases at diagnosis. No differences were found regarding the primary tumor site. Only the national study group affiliation had an influence on participation. Participation decreased linearly with trial progress up to 20% at the final time point of QoL assessment. This study demonstrates the feasibility of international cooperation for the purpose of assessing and understanding the QoL of pediatric and adolescent/young adult patients with cancer. Future outcomes of this QoL substudy will help to adapt interventions to improve QoL.

• Terrisse, Safae; Karamouza, Eleni; Parker, Chris C.; Sartor, A. Oliver; James, Nicholas D. & Pirrie, Sarah [Vis alle 14 forfattere av denne artikkelen] (2019). Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: A meta-analysis of individual patient data from randomized clinical trials. JAMA Oncology. ISSN 2374-2437. doi: 10.1001/jamaoncol.2019.4097. Fulltekst i vitenarkiv
• Kværner, Ane Sørlie; Minaguchi, Jun; Yamani, Naouale El; Henriksen, Christine; Ræder, Hanna & Paur, Ingvild [Vis alle 12 forfattere av denne artikkelen] (2018). DNA damage in blood cells in relation to chemotherapy and nutritional status in colorectal cancer patients — A pilot study. DNA Repair. ISSN 1568-7864. 63, s. 16–24. doi: 10.1016/j.dnarep.2018.01.005. Fulltekst i vitenarkiv
• Høland, Maren; Kolberg, Matthias; Danielsen, Stine Aske; Bjerkehagen, Bodil; Eilertsen, Ina Andrassy & Hektoen, Merete [Vis alle 14 forfattere av denne artikkelen] (2018). Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Modern Pathology. ISSN 0893-3952. s. 1–14. doi: 10.1038/s41379-018-0074-y. Fulltekst i vitenarkiv Vis sammendrag

  Malignant peripheral nerve sheath tumor is a rare and aggressive disease with poor treatment response, mainly affecting adolescents and young adults. Few molecular biomarkers are used in the management of this cancer type, and although TP53 is one of few recurrently mutated genes in malignant peripheral nerve sheath tumor, the mutation prevalence and the corresponding clinical value of the TP53 network remains unsettled. We present a multi-level molecular study focused on aberrations in the TP53 network in relation to patient outcome in a series of malignant peripheral nerve sheath tumors from 100 patients and 38 neurofibromas, including TP53 sequencing, high-resolution copy number analyses of TP53 and MDM2, and gene expression profiling. Point mutations in TP53 were accompanied by loss of heterozygosity, resulting in complete loss of protein function in 8.2% of the malignant peripheral nerve sheath tumors. Another 5.5% had MDM2 amplification. TP53 mutation and MDM2 amplification were mutually exclusive and patients with either type of aberration in their tumor had a worse prognosis, compared to those without (hazard ratio for 5-year disease-specific survival 3.5, 95% confidence interval 1.78–6.98). Both aberrations had similar consequences on the gene expression level, as analyzed by a TP53-associated gene signature, a property also shared with the copy number aberrations and/or loss of heterozygosity at the TP53 locus, suggesting a common “TP53-mutated phenotype” in as many as 60% of the tumors. This was a poor prognostic phenotype (hazard ratio = 4.1, confidence interval:1.7–9.8), thus revealing a TP53-non-aberrant patient subgroup with a favorable outcome. The frequency of the “TP53-mutated phenotype” warrants explorative studies of stratified treatment strategies in malignant peripheral nerve sheath tumor.

• Ræder, Hanna; Henriksen, Christine; Bøhn, Siv Kjølsrud; Vilbo, Anne-Rikke; Henriksen, Hege & Kværner, Ane Sørlie [Vis alle 10 forfattere av denne artikkelen] (2018). Agreement between PG-SGA category and fat-free mass in colorectal cancer patients. Clinical Nutrition ESPEN. ISSN 2405-4577. 27, s. 24–31. doi: 10.1016/j.clnesp.2018.07.005. Fulltekst i vitenarkiv Vis sammendrag

  Background and aims Low fat-free mass (FFM) is associated with adverse outcomes in colorectal cancer (CRC) patients. Patient-Generated Subjective Global Assessment (PG-SGA) is a widely used tool developed to detect patients with malnutrition or at risk of malnutrition. The aim of this study was to investigate the agreement between PG-SGA category and FFM in patients with non-metastatic CRC. Methods Ninety-seven patients were included and categorized as well nourished (PG-SGA:A, n = 67) or malnourished (PG-SGA:B, n = 30). No patients were severely malnourished (PG-SGA: C). Bioelectrical impedance analysis (BIA) was used to assess FFM. Low FFM was defined as low fat-free mass index (FFMI) according to cut-off values recently proposed by The European Society for Clinical Nutrition and Metabolism (ESPEN). Results Twenty-nine percent of the patients were identified with low FFMI. The proportion with low FFMI was significantly higher among patients classified as malnourished by PG-SGA compared to well nourished (p = 0.015). The sensitivity was however low, as the PG-SGA categorization classified only 50.0% of the patients with low FFMI as malnourished (PG-SGA B). Using the PG-SGA scores (cut-off point > 4), the sensitivity increased to 60.7%. Physical examination in the PG-SGA identified only 64.3% of the patients with low FFMI as muscle depleted. Conclusion Our results indicate a low agreement between PG-SGA category and low FFMI among patients with non-metastatic CRC. In clinical practice, PG-SGA should be supplemented by muscle mass assessments by BIA or other methods in order to detect low FFM in this patient group.

• Henriksen, Hege; Berntsen, Sveinung; Paur, Ingvild; Zucknick, Manuela; Skjetne, Anne Juul & Bøhn, Siv Kjølsrud [Vis alle 10 forfattere av denne artikkelen] (2018). Validation of two short questionnaires assessing physical activity in colorectal cancer patients. BMC sports science, medicine and rehabilitation. 10:8(8), s. 1–12. doi: 10.1186/s13102-018-0096-2. Fulltekst i vitenarkiv Vis sammendrag

  Background In order to investigate the impact of adherence to recommendations of physical activity and sedentary time on health outcomes in clinical trials, there is a need for feasible tools such as questionnaires that can give representative estimates of these measures. The primary aim of the present study was to validate two such questionnaires and their ability to estimate adherence to the recommendations of physical activity defined as moderate-to- vigorous physical activity or moderate physical activity of at least 150 min/week in colorectal cancer patients. Secondarily, self-reported sedentary time from the HUNT-PAQ was also evaluated. Methods Participants from 'The Norwegian dietary guidelines and colorectal cancer survival-study’ (CRC-NORDIET study) completed two short questionnaires; the NORDIET-FFQ (n = 78) and the HUNT-PAQ (n = 77). The physical activity monitor SenseWear Armband Mini was used as the reference method during seven consecutive days. Results The NORDIET-FFQ provided better estimates of time in moderate-to- vigorous physical activity and moderate physical activity than the HUNT-PAQ. The NORDIET-FFQ was unable to rank individual time in moderate-to- vigorous physical activity and moderate physical activity (Spearman’s rho = 0.08, p = 0.509 and Spearman’s rho rho = 0.01, p = 0.402, respectively). All intensities were under-reported by the HUNT-PAQ, but ranking of individual time in moderate physical activity and sedentary time were acceptable among women only (Spearman’s rho = 0.37, p = 0.027 and Spearman’s rho = 0.36, p = 0.035, respectively). The HUNT-PAQ correctly classified 71% of those not meeting the recommendations (sensitivity), and the NORDIET-FFQ correctly classified 63% of those who met the recommendations (specificity). About 67% and 33% reported to meet the recommendation of moderate-to- vigorous physical activity with the NORDIET-FFQ and HUNT-PAQ, respectively, whereas 55% actually met the moderate-to- vigorous physical activity according to the SenseWear Armband Mini. Conclusions The NORDIET-FFQ provided better specificity and better estimates of PA than the HUNT-PAQ. The HUNT-PAQ provided better sensitivity, and provided better ranking of PA and sedentary time among women than NORDIET-FFQ. It is important to be aware of the limitations documented in the present study. Trial registration The study is registered on the National Institutes of Health Clinical Trials (Identifier: NCT01570010). Registered 4 April 2012.

• Henriksen, Hege; Carlsen, Monica Hauger; Paur, Ingvild; Berntsen, Sveinung; Bøhn, Siv Kjølsrud & Skjetne, Anne Juul [Vis alle 11 forfattere av denne artikkelen] (2018). Relative validity of a short food frequency questionnaire assessing adherence to the Norwegian dietary guidelines among colorectal cancer patients. Food & Nutrition Research (FNR). ISSN 1654-6628. 62:1306, s. 1–15. doi: 10.29219/fnr.v62.1306. Fulltekst i vitenarkiv
• Paur, Ingvild; Slåttholm, Mari Arnøy; Ryel, Anne Lise & Smeland, Sigbjørn (2018). Riktig ernæring er viktig for kreftpasienter. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 138(11), s. 1–4. doi: 10.4045/tidsskr.18.0072. Fulltekst i vitenarkiv
• Ferrari, Stefano; Bielack, Stefan S.; Smeland, Sigbjørn; Longhi, Alessandra; Egerer, Gerlinde & Hall, Kirsten Sundby [Vis alle 33 forfattere av denne artikkelen] (2018). EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori (Milano). ISSN 0300-8916. 104(1), s. 30–36. doi: 10.5301/tj.5000696. Fulltekst i vitenarkiv
• Ræder, Hanna; Kværner, Ane Sørlie; Henriksen, Christine; Florholmen, Geir; Henriksen, Hege & Bøhn, Siv Kjølsrud [Vis alle 9 forfattere av denne artikkelen] (2017). Validity of bioelectrical impedance analysis in estimation of fat-free mass in colorectal cancer patients. Clinical Nutrition. ISSN 0261-5614. 37(1), s. 292–300. doi: 10.1016/j.clnu.2016.12.028. Fulltekst i vitenarkiv Vis sammendrag

  Background & aims: Bioelectrical impedance analysis (BIA) is an accessible and cheap method to measure fat-free mass (FFM). However, BIA estimates are subject to uncertainty in patient populations with altered body composition and hydration. The aim of the current study was to validate a whole-body and a segmental BIA device against dual-energy X-ray absorptiometry (DXA) in colorectal cancer (CRC) patients, and to investigate the ability of different empiric equations for BIA to predict DXA FFM (FFMDXA). Methods: Forty-three non-metastatic CRC patients (aged 50–80 years) were enrolled in this study. Whole-body and segmental BIA FFM estimates (FFMwhole-bodyBIA, FFMsegmentalBIA) were calculated using 14 empiric equations, including the equations from the manufacturers, before comparison to FFMDXA estimates. Results: Strong linear relationships were observed between FFMBIA and FFMDXA estimates for all equations (R2 = 0.94–0.98 for both devices). However, there were large discrepancies in FFM estimates depending on the equations used with mean differences in the ranges −6.5–6.8 kg and −11.0–3.4 kg for whole-body and segmental BIA, respectively. For whole-body BIA, 77% of BIA derived FFM estimates were significantly different from FFMDXA, whereas for segmental BIA, 85% were significantly different. For whole-body BIA, the Schols* equation gave the highest agreement with FFMDXA with mean difference ±SD of −0.16 ± 1.94 kg (p = 0.582). The manufacturer's equation gave a small overestimation of FFM with 1.46 ± 2.16 kg (p < 0.001) with a tendency towards proportional bias (r = 0.28, p = 0.066). For segmental BIA, the Heitmann* equation gave the highest agreement with FFMDXA (0.17 ± 1.83 kg (p = 0.546)). Using the manufacturer's equation, no difference in FFM estimates was observed (−0.34 ± 2.06 kg (p = 0.292)), however, a clear proportional bias was detected (r = 0.69, p < 0.001). Both devices demonstrated acceptable ability to detect low FFM compared to DXA using the optimal equation. Conclusion: In a population of non-metastatic CRC patients, mostly consisting of Caucasian adults and with a wide range of body composition measures, both the whole-body BIA and segmental BIA device provide FFM estimates that are comparable to FFMDXA on a group level when the appropriate equations are applied. At the individual level (i.e. in clinical practice) BIA may be a valuable tool to identify patients with low FFM as part of a malnutrition diagnosis.

• Henriksen, Hege; Ræder, Hanna; Bøhn, Siv Kjølsrud; Paur, Ingvild; Kværner, Ane Sørlie & Billington, Siv Åshild [Vis alle 14 forfattere av denne artikkelen] (2017). The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: A food-based multicentre randomized controlled trial. BMC Cancer. 17(1). doi: 10.1186/s12885-017-3072-4. Fulltekst i vitenarkiv Vis sammendrag

  Background Colorectal cancer survivors are not only at risk for recurrent disease but also at increased risk of comorbidities such as other cancers, cardiovascular disease, diabetes, hypertension and functional decline. In this trial, we aim at investigating whether a diet in accordance with the Norwegian food-based dietary guidelines and focusing at dampening inflammation and oxidative stress will improve long-term disease outcomes and survival in colorectal cancer patients. Methods/design This paper presents the study protocol of the Norwegian Dietary Guidelines and Colorectal Cancer Survival study. Men and women aged 50–80 years diagnosed with primary invasive colorectal cancer (Stage I-III) are invited to this randomized controlled, parallel two-arm trial 2–9 months after curative surgery. The intervention group (n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention for 14 years. The control group (n = 250) receives no dietary intervention other than standard clinical care. Both groups are offered equal general advice of physical activity. Patients are followed-up at 6 months and 1, 3, 5, 7, 10 and 15 years after baseline. The study center is located at the Department of Nutrition, University of Oslo, and patients are recruited from two hospitals within the South-Eastern Norway Regional Health Authority. Primary outcomes are disease-free survival and overall survival. Secondary outcomes are time to recurrence, cardiovascular disease-free survival, compliance to the dietary recommendations and the effects of the intervention on new comorbidities, intermediate biomarkers, nutrition status, physical activity, physical function and quality of life. Discussion The current study is designed to gain a better understanding of the role of a healthy diet aimed at dampening inflammation and oxidative stress on long-term disease outcomes and survival in colorectal cancer patients. Since previous research on the role of diet for colorectal cancer survivors is limited, the study may be of great importance for this cancer population. Trial registration ClinicalTrials.gov Identifier: NCT01570010 .

• Paur, Ingvild; Lilleby, Wolfgang; Bøhn, Siv Kjølsrud; Hulander, Erik; Klein, Willibrord & Vlatkovic, Ljiljana [Vis alle 19 forfattere av denne artikkelen] (2016). Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clinical Nutrition. ISSN 0261-5614. 36(3), s. 672–679. doi: 10.1016/j.clnu.2016.06.014. Fulltekst i vitenarkiv Vis sammendrag

  Background & aims: The effect of lycopene-containing foods in prostate cancer development remains undetermined. We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients. Methods: Prior to their curative treatment, 79 patients with prostate cancer were randomized to a nutritional intervention with either 1) tomato products containing 30 mg lycopene per day; 2) tomato products plus selenium, omega-3 fatty acids, soy isoflavones, grape/pomegranate juice, and green/black tea (tomato-plus); or 3) control diet for 3 weeks. Results: The main analysis, which included patients in all risk categories, did not reveal differences in changes of PSA-values between the intervention and control groups. Post-hoc, exploratory analyses within intermediate risk (n = 41) patients based on tumor classification and Gleason score post-surgery, revealed that median PSA decreased significantly in the tomato group as compared to controls (−2.9% and +6.5% respectively, p = 0.016). In separate post-hoc analyses, we observed that median PSA-values decreased by 1% in patients with the highest increases in plasma lycopene, selenium and C20:5 n-3 fatty acid, compared to an 8.5% increase in the patients with the lowest increase in lycopene, selenium and C20:5 n-3 fatty acid (p = 0.003). Also, PSA decreased in patients with the highest increase in lycopene alone (p = 0.009). Conclusions: Three week nutritional interventions with tomato-products alone or in combination with selenium and n-3 fatty acids lower PSA in patients with non-metastatic prostate cancer. Our observation suggests that the effect may depend on both aggressiveness of the disease and the blood levels of lycopene, selenium and omega-3 fatty acids.

• Russnes, Kjell Magne; Möller, Elisabeth; Wilson, Kathryn M.; Carlsen, Monica Hauger; Blomhoff, Rune & Smeland, Sigbjørn [Vis alle 10 forfattere av denne artikkelen] (2016). Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study. BMC Cancer. 16:438, s. 1–12. doi: 10.1186/s12885-016-2486-8. Fulltekst i vitenarkiv Vis sammendrag

  Background The total intake of dietary antioxidants may reduce prostate cancer risk but available data are sparse and the possible role of supplements unclear. We investigated the potential association between total and dietary antioxidant intake and prostate cancer in a Swedish population. Methods We used FFQ data from 1499 cases and 1112 controls in the population based case–control study Cancer of the Prostate in Sweden (CAPS). The ferric reducing antioxidant potential (FRAP) assay was used to assess the total antioxidant capacity (TAC) of diet and supplements. We calculated odds ratios (ORs) for the risk of prostate cancer across quintiles of antioxidant intake from all foods, from fruit and vegetables only, and from dietary supplements using unconditional logistic regression. Results Coffee comprised 62 % of the dietary antioxidant intake, tea 4 %, berries 4 %, chocolate 2 %, and boiled potatoes 2 %. In total 19 % and 13 % of the population took multivitamins and supplemental Vitamin C respectively, on a regular basis. Antioxidant intake from all foods and from fruits and vegetables separately measured by the FRAP assay was not associated with prostate cancer risk. For antioxidant intake from supplements we found a positive association with total, advanced, localized, high grade and low grade prostate cancer in those above median supplemental TAC intake of users compared to non-users (Adjusted ORs for total prostate cancer: 1.37, 95 % CI 1.08–1.73, advanced: 1.51, 95 % CI 1.11–2.06, localized: 1.36. 95 % CI 1.06–1.76, high grade 1.60, 95 % CI 1.06–2.40, low grade 1.36, 95 % CI 1.03–1.81). A high intake of coffee (≥6 cups/day) was associated with a possible risk reduction of fatal and significantly with reduced risk for high grade prostate cancer, adjusted OR: 0.45 (95 % CI: 0.22–0.90), whereas a high intake of chocolate was positively associated with risk of total, advanced, localized and low grade disease (adjusted OR for total: 1.43, 95 % CI 1.12–1.82, advanced: 1.40, 95 % CI 1.01–1.96, localized: 1.43, 95 % CI 1.08–1.88, low-grade: 1.41, 95 % CI 1.03–1.93). Conclusions Total antioxidant intake from diet was not associated with prostate cancer risk. Supplement use may be associated with greater risk of disease.

• Thorsen, Lene; Dahl, Alv A; Nystad, Roy; Kiserud, Cecilie E.; Geirdal, Amy Østertun & Smeland, Sigbjørn (2016). Baseline characteristics in female cancer patients with unimproved work status after an outpatient rehabilitation program and health changes during the intervention. SpringerPlus. 5:1009. doi: 10.1186/s40064-016-2663-x. Fulltekst i vitenarkiv Vis sammendrag

  Purpose To improve work ability and health-related quality of life (HRQOL) cancer patients were offered a “Rapid-Return to Work” program. However, several patients did not improve their work status after completing the program. The first aim of this study was to identify the proportion of patients with unimproved work status 6 months after the program (follow-up). The second aim was to identify baseline characteristics associated with unimproved work status and the third aim to measure changes in HRQOL from baseline to follow-up in the unimproved compared to the improved group. Methods The program consisted of patient education, group discussions and physical activity during a full day weekly for 7 weeks. All patients completed a questionnaire at baseline and follow-up, covering demographic-, cancer-related-, co-morbidity and lifestyle variables, HRQOL (EORTC QLQ-C30) and fatigue (Fatigue Questionnaire). Results 106 female cancer patients completed the program and responded to the follow-up. Thirty-six percent had unimproved work status. Patients in the unimproved group more frequently were in paired relations and had more fatigue at baseline than the improved group. Whereas patients in the improved group increased in 14 of 19 HRQOL parameters, the unimproved group increased in seven of these parameters. Both groups experienced improvement concerning fatigue. Conclusion After the program more than one third of the participants did not improve their work status. Patients in paired relations and with more fatigue at baseline were more likely to have unimproved work status. Those within the unimproved group experienced less improvement in HRQOL parameters during the program than those in the improved group.

• Marina, Neyssa M.; Smeland, Sigbjørn; Bielack, Stefan S.; Bernstein, Mark; Jovic, Gordana & Krailo, Mark D. [Vis alle 53 forfattere av denne artikkelen] (2016). Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. The Lancet Oncology. ISSN 1470-2045. 17(10), s. 1396–1408. doi: 10.1016/S1470-2045(16)30214-5. Fulltekst i vitenarkiv
• Kolberg, Matthias; Høland, Maren; Lind, Guro Elisabeth; Ågesen, Trude Holmeide; Skotheim, Rolf Inge & Hall, Kirsten Sundby [Vis alle 11 forfattere av denne artikkelen] (2015). Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection. Molecular Oncology. ISSN 1574-7891. 9(6), s. 1129–1139. doi: 10.1016/j.molonc.2015.02.005. Fulltekst i vitenarkiv
• Whelan, Jeremy S.; Bielack, Stefan S.; Marina, Neyssa; Smeland, Sigbjørn; Jovic, Gordana & Hook, Jane M. [Vis alle 41 forfattere av denne artikkelen] (2015). EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Annals of Oncology. ISSN 0923-7534. 26(2), s. 407–414. doi: 10.1093/annonc/mdu526. Fulltekst i vitenarkiv
• Bielack, Stefan S.; Smeland, Sigbjørn; Whelan, Jeremy S.; Marina, Neyssa; Jovic, Gordana & Hook, Jane M. [Vis alle 49 forfattere av denne artikkelen] (2015). Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. Journal of Clinical Oncology. ISSN 0732-183X. 33(20), s. 2279–2287. doi: 10.1200/JCO.2014.60.0734. Fulltekst i vitenarkiv
• Danielsen, Stine Aske; Lind, Guro Elisabeth; Kolberg, Matthias; Høland, Maren; Bjerkehagen, Bodil & Hall, Kirsten Sundby [Vis alle 11 forfattere av denne artikkelen] (2015). Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro-Oncology. ISSN 1522-8517. 17(1), s. 63–69. doi: 10.1093/neuonc/nou140. Fulltekst i vitenarkiv
• Kolberg, Matthias; Smeland, Sigbjørn & Lothe, Ragnhild A (2015). Adjuvant chemotherapy in malignant peripheral nerve sheath tumors. Chemotherapy: Open Access. ISSN 2167-7700. 4(3), s. 158–158. doi: 10.4172/2167-7700.1000158. Fulltekst i vitenarkiv
• Bruheim, Marie; Woods, Kadra, V; Smeland, Sigbjørn & Nortvedt, Monica Wammen (2014). An educational program to transition oncology nurses at the norwegian radium hospital to an evidence-based practice model: Development, implementation, and preliminary outcomes. Journal of Cancer Education. ISSN 0885-8195. 29(2), s. 224–232. doi: 10.1007/s13187-013-0575-9. Fulltekst i vitenarkiv
• Oldervoll, Line Merethe; Thorsen, Lene; Kaasa, Stein; Fosså, Sophie Dorothea; Dahl, Alv A & Småstuen, MC [Vis alle 10 forfattere av denne artikkelen] (2014). Inpatient versus outpatient rehabilitation after breast and gynecological cancers – a comparative study. International Journal of Physical Medicine & Rehabilitation. 2(187). Fulltekst i vitenarkiv
• Russnes, Kjell Magne; Wilson, Kathryn M.; Epstein, Mara M.; Kasperzyk, Julie L.; Stampfer, Meir J. & Kenfield, Stacey A. [Vis alle 11 forfattere av denne artikkelen] (2014). Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-Up Study. International Journal of Cancer. ISSN 0020-7136. 134(5), s. 1156–1165. doi: 10.1002/ijc.28438. Fulltekst i vitenarkiv
• Bjerkehagen, Bodil; Småstuen, Milada C; Hall, Kirsten Sundby; Skjeldal, Sigmund; Bruland, Øyvind & Smeland, Sigbjørn [Vis alle 8 forfattere av denne artikkelen] (2013). Incidence and mortality of second sarcomas – A population-based study. European Journal of Cancer. ISSN 0959-8049. 49(15), s. 3292–3302. doi: 10.1016/j.ejca.2013.05.017. Fulltekst i vitenarkiv
• Stensvold, Andreas; Dahl, Alv A; Brennhovd, Bjørn; Småstuen, Milada C; Fosså, Sophie Dorothea & Lilleby, Wolfgang [Vis alle 9 forfattere av denne artikkelen] (2013). Bother problems in prostate cancer patients after curative treatment. Urologic Oncology. ISSN 1078-1439. 31(7), s. 1067–1078. doi: 10.1016/j.urolonc.2011.12.020. Fulltekst i vitenarkiv
• Kolberg, Matthias; Høland, Maren; Ågesen, Trude Holmeide; Brekke, Helge Roar; Liestøl, Knut & Hall, Kirsten Sundby [Vis alle 10 forfattere av denne artikkelen] (2013). Survival meta-analyses for &gt; 1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-Oncology. ISSN 1522-8517. 15(2), s. 135–147. doi: 10.1093/neuonc/nos287. Fulltekst i vitenarkiv
• Collins, Marnie; Wilhelm, Miriam; Conyers, Rachel; Herschtal, Alan; Whelan, Jeremy & Bielack, Stefan [Vis alle 17 forfattere av denne artikkelen] (2013). Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. Journal of Clinical Oncology. ISSN 0732-183X. 31(18), s. 2303–U130. doi: 10.1200/JCO.2012.43.8598. Fulltekst i vitenarkiv
• Luksch, R; Tienghi, A; Hall, Kirsten Sundby; Fagioli, F; Picci, P & Barbieri, E [Vis alle 19 forfattere av denne artikkelen] (2012). Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Annals of Oncology. ISSN 0923-7534. 23(11), s. 2970–2976. doi: 10.1093/annonc/mds117. Fulltekst i vitenarkiv
• Bjerkehagen, Bodil; Småstuen, Milada C; Hall, Kirsten Sundby; Skjeldal, Sigmund; Smeland, Sigbjørn & Fosså, Sophie Dorothea (2012). Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival? British Journal of Cancer. ISSN 0007-0920. 106(2), s. 297–306. doi: 10.1038/bjc.2011.559. Fulltekst i vitenarkiv
• Wien, Tale Norbye; Pike, Eva; Wisløff, Torbjørn; Staff, Anne Cathrine; Smeland, Sigbjørn & Klemp, Marianne (2012). Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open. 2. doi: 10.1136/bmjopen-2011-000653. Fulltekst i vitenarkiv
• Stensvold, Andreas; Dahl, Alv A; Brennhovd, Bjørn; Småstuen, Milada C; Fosså, Sophie Dorothea & Lilleby, Wolfgang [Vis alle 8 forfattere av denne artikkelen] (2012). Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. The Prostate. ISSN 0270-4137. 72(6), s. 668–676. doi: 10.1002/pros.21470. Fulltekst i vitenarkiv
• Bøhn, Siv Kjølsrud; Russnes, Kjell Magne; Sakhi, Amrit Kaur; Thoresen, Magne; Holden, Marit & Moskaug, Jan Øivind [Vis alle 10 forfattere av denne artikkelen] (2012). Stress associated gene expression in blood cells is related to outcome in radiotherapy treated head and neck cancer patients. BMC Cancer. 12. doi: 10.1186/1471-2407-12-426. Fulltekst i vitenarkiv Vis sammendrag

  Background We previously observed that a radiotherapy-induced biochemical response in plasma was associated with favourable outcome in head and neck squamous carcinoma cancer (HNSCC) patients. The aim of the present study was to compare stress associated blood cell gene expression between two sub-groups of HNSCC patients with different biochemical responses to radiotherapy. Methods Out of 87 patients (histologically verified), 10 biochemical ‘responders’ having a high relative increase in plasma oxidative damage and a concomitant decrease in plasma antioxidants during radiotherapy and 10 ‘poor-responders’ were selected for gene-expression analysis and compared using gene set enrichment analysis. Results There was a significant induction of stress-relevant gene-sets in the responders following radiotherapy compared to the poor-responders. The relevance of the involvement of similar stress associated gene expression for HNSCC cancer and radioresistance was verified using two publicly available data sets of 42 HNSCC cases and 14 controls (GEO GSE6791), and radiation resistant and radiation sensitive HNSCC xenografts (E-GEOD-9716). Conclusions Radiotherapy induces a systemic stress response, as revealed by induction of stress relevant gene expression in blood cells, which is associated to favourable outcome in a cohort of 87 HNSCC patients. Whether these changes in gene expression reflects a systemic effect or are biomarkers of the tumour micro-environmental status needs further study.

• Stensvold, Andreas; Dahl, Alv A; Fosså, Sophie Dorothea; Axcrona, Karol; Lilleby, Wolfgang & Brennhovd, Bjørn [Vis alle 7 forfattere av denne artikkelen] (2011). Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center. Acta Oncologica. ISSN 0284-186X. 50(3), s. 408–414. doi: 10.3109/0284186X.2010.492236. Fulltekst i vitenarkiv
• Smeland, Sigbjørn; Bruland, Øyvind; Hjorth, Lars; Brosjö, Otte; Bjerkehagen, Bodil & Österlundh, Gustaf [Vis alle 11 forfattere av denne artikkelen] (2011). Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma 63 patients with a minimum follow-up of 4 years. Acta Orthopaedica. ISSN 1745-3674. 82(2), s. 211–216. doi: 10.3109/17453674.2011.566141. Fulltekst i vitenarkiv
• Hjortland, Geir Olav; Meza, Leonardo Zepeda; Beiske, Klaus; Ree, Anne Hansen; Tveito, Siri & Høifødt, Hanne Kleppe [Vis alle 12 forfattere av denne artikkelen] (2011). Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer. 11. doi: 10.1186/1471-2407-11-455. Fulltekst i vitenarkiv Vis sammendrag

  Background Metastatic progression due to development or enrichment of therapy-resistant tumor cells is eventually lethal. Molecular characterization of such chemotherapy resistant tumor cell clones may identify markers responsible for malignant progression and potential targets for new treatment. Here, in a case of stage IV adenocarcinoma of the gastroesophageal junction, we report the successful genome wide analysis using array comparative genomic hybridization (CGH) of DNA from only fourteen tumor cells using a bead-based single cell selection method from a bone metastasis progressing during chemotherapy. Case presentation In a case of metastatic adenocarcinoma of the gastroesophageal junction, the progression of bone metastasis was observed during a chemotherapy regimen of epirubicin, oxaliplatin and capecitabine, whereas lung-, liver and lymph node metastases as well as the primary tumor were regressing. A bone marrow aspirate sampled at the site of progressing metastasis in the right iliac bone was performed, and single cell molecular analysis using array-CGH of Epithelial Specific Antigen (ESA)-positive metastatic cells, and revealed two distinct regions of amplification, 12p12.1 and 17q12-q21.2 amplicons, containing the KRAS (12p) and ERBB2 (HER2/NEU) (17q) oncogenes. Further intrapatient tumor heterogeneity of these highlighted gene copy number changes was analyzed by fluorescence in situ hybridization (FISH) in all available primary and metastatic tumor biopsies, and ErbB2 protein expression was investigated by immunohistochemistry. ERBB2 was heterogeneously amplified by FISH analysis in the primary tumor, as well as liver and bone metastasis, but homogenously amplified in biopsy specimens from a progressing bone metastasis after three initial cycles of chemotherapy, indicating a possible enrichment of erbB2 positive tumor cells in the progressing bone marrow metastasis during chemotherapy. A similar amplification profile was detected for wild-type KRAS, although more heterogeneously expressed in the bone metastasis progressing on chemotherapy. Correspondingly, the erbB2 protein was found heterogeneously expressed by immunohistochemical staining of the primary tumor of the gastroesophageal junction, while negative in liver and bone metastases, but after three initial cycles of palliative chemotherapy with epirubicin, oxaliplatin and capecetabine, the representative bone metastasis stained strongly positive for erbB2. Conclusion Global analysis of genetic aberrations, as illustrated by performing array-CGH analysis on genomic DNA from only a few selected tumor cells of interest sampled from a progressing bone metastasis, can identify relevant therapeutic targets and genetic aberrations involved in malignant progression, thus emphasizing the importance and feasibility of this powerful tool on the road to more personalized cancer therapies in the future.

• Johansson, Lars; Andersen, Lene Frost; Iversen, Per Ole; Smeland, Sigbjørn & Blomhoff, Rune (2011). Nye norske matvarebaserte kostråd. Nordisk Nutrition. ISSN 1654-8337. 2, s. 12–15. Fulltekst i vitenarkiv
• Ferrari, S; Hall, Kirsten Sundby; Luksch, R; Tienghi, A; Wiebe, T & Fagioli, F [Vis alle 20 forfattere av denne artikkelen] (2011). Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Annals of Oncology. ISSN 0923-7534. 22(5), s. 1221–1227. doi: 10.1093/annonc/mdq573. Fulltekst i vitenarkiv
• Brekke, Helge Roar; Ribeiro, Franclim R; Kolberg, Matthias; Ågesen, Trude H.; Lind, Guro Elisabeth & Eknæs, Mette [Vis alle 15 forfattere av denne artikkelen] (2010). Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group. Journal of Clinical Oncology. ISSN 0732-183X. 28(9), s. 1573–1582. doi: 10.1200/JCO.2009.24.8989. Fulltekst i vitenarkiv
• Whelan, Jeremy; Patterson, Daniel; Perisoglou, Martha; Bielack, Stefan; Marina, Neyssa & Smeland, Sigbjørn [Vis alle 7 forfattere av denne artikkelen] (2010). The Role of Interferons in the Treatment of Osteosarcoma. Pediatric Blood & Cancer. ISSN 1545-5009. 54(3), s. 350–354. doi: 10.1002/pbc.22136. Fulltekst i vitenarkiv
• Muller, Christoph Rainer; Namløs, Heidi Maria; Bjerner, Johan; Østensen, Ingrid Helene Garmann; Sæter, Gunnar & Smeland, Sigbjørn [Vis alle 8 forfattere av denne artikkelen] (2010). Characterization of Treatment Response to Recombinant Interferon-α2b in Osteosarcoma Xenografts. Journal of Cancer Science & Therapy. 2(1), s. 16–25. doi: 10.4172/1948-5956.1000018. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Skaara, Turid Rygh; Puco, Katarina; Dyvik, Ingrid; Slørdahl, Kathinka Schmidt; Falk, Ragnhild Sørum & Brabrand, Sigmund [Vis alle 32 forfattere av denne artikkelen] (2026). Alteration-matched therapy in advanced lung cancer: results from the IMPRESS-Norway study. Fulltekst i vitenarkiv
• Bjørgo, Elisa; Ånensen, Nina; Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn & Tasken, Kjetil [Vis alle 7 forfattere av denne artikkelen] (2026). Merging clinical research and standard healthcare – Nordic Precision Cancer Medicine Symposium 2025. Acta Oncologica. ISSN 0284-186X. 65, s. 185–185. doi: 10.2340/1651-226x.2026.45168. Fulltekst i vitenarkiv
• Brabrand, Sigmund; Steinskog, Eli Sihn Samdal; Blix, Egil Støre; Flobak, Åsmund; Puco, Katarina & Fagereng, Gro Live [Vis alle 20 forfattere av denne artikkelen] (2025). 3137O IMPRESS-Norway: A nationwide precision-oncology study for off-label targeted therapies - Results from the first 1,740 patients. doi: 10.1016/j.annonc.2025.08.1609. Fulltekst i vitenarkiv
• Guren, Marianne; Malinen, Eirik; Smeland, Sigbjørn; Straume, Oddbjørn; Waldeland, Einar & Tasken, Kjetil (2024). Kreftbehandling: Nå er det mulig å tilby mer skånsom stråleterapi for kreftpasienter. s. 34–35. doi: https:/e-avis.aftenposten.no/p/aftenposten/2024-12-27/a/na-er-det-mulig-a-tilby-mer-skansom-straleterapi-for-kreftpasienter/611/1797967/59577861. Fulltekst i vitenarkiv
• Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Tasken, Kjetil; Smeland, Sigbjørn & Helland, Åslaug (2024). Presisjonsmedisin innen kreft. [Journal]. Aftenposten (Persontilpasset Behandling – Addendum to AP). Fulltekst i vitenarkiv
• Dyvik, Ingrid; Fagereng, Gro Live; Lien, Tonje; Nygaard, Vigdis; Silwal-Pandit, Laxmi & Noon, J Christopher [Vis alle 20 forfattere av denne artikkelen] (2024). Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial. Fulltekst i vitenarkiv
• Helland, Åslaug; Steinskog, Eli Sihn Samdal; Blix, Egil Støre; Flobak, Åsmund; Brabrand, Sigmund & Puco, Katarina [Vis alle 20 forfattere av denne artikkelen] (2024). Hever kvaliteten på behandling av kreft. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 144(1), s. 52–53. doi: 10.4045/tidsskr.23.0740. Fulltekst i vitenarkiv Vis sammendrag

  Alle norske sykehus med kreftavdeling deltar i en nasjonal kreftbehandlingsstudie. Den er aktuell for pasienter med avansert kreftsykdom etter standard behandling.

• Bjørgo, elisa; Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Tasken, Kjetil & Helland, Åslaug (2024). Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 – merging clinical research and standard healthcare. Acta Oncologica. ISSN 0284-186X. 63, s. 487–490. doi: 10.2340/1651-226X.2024.24954. Fulltekst i vitenarkiv
• Bjørgo, Elisa; Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Tasken, Kjetil & Helland, Åslaug (2023). ACTA Oncologica Nordic Precision Cancer Medicine Symposium 2023 – Merging Clinical Research and Standard Healthcare. Acta Oncologica. ISSN 0284-186X. Fulltekst i vitenarkiv
• Heia, Ingvild; Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky & Smeland, Sigbjørn (2023). Innføring av presisjonsmedisin innen kreft i Norge. [Journal]. Aftenposten (Innstikk «Persontilpasset behandling). Fulltekst i vitenarkiv
• Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Gravli, Trine H.; Smeland, Sigbjørn & Kaasa, Stein (2023). Pasientsentrert kreftbehandling. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 143(1). doi: 10.4045/tidsskr.22.0668. Fulltekst i vitenarkiv
• Tasken, Kjetil; Russnes, Hege Elisabeth Giercksky; Aas, Eline; Bjørge, Line; Blix, Egil Støre & Ahlquist, Terje C. [Vis alle 116 forfattere av denne artikkelen] (2022). A national precision cancer medicine implementation initiative for Norway. Nature Medicine. ISSN 1078-8956. 28(5), s. 885–887. doi: 10.1038/s41591-022-01777-4. Fulltekst i vitenarkiv
• Budde, Axel; Baust, Katja; Weinhold, Leonie; Bernstein, Mark; Bielack, Stefan & Dhooge, Catharina [Vis alle 19 forfattere av denne artikkelen] (2022). Erratum to ‘Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma’ [Eur J Cancer 170 (2022) 209-235, (S0959804922001629), (10.1016/j.ejca.2022.03.018)]. European Journal of Cancer. ISSN 0959-8049. 177, s. 208–209. doi: 10.1016/j.ejca.2022.06.053. Fulltekst i vitenarkiv
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Vis alle 53 forfattere av denne artikkelen] (2022). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5). Journal of Translational Medicine. 20(1). doi: 10.1186/s12967-022-03518-0. Fulltekst i vitenarkiv
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Vis alle 53 forfattere av denne artikkelen] (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine. 20(1), s. 1–11. doi: 10.1186/s12967-022-03432-5. Fulltekst i vitenarkiv Vis sammendrag

  Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer specific pathways have been developed and approved for subgroups of patients. These drugs might just as well be efficient in other diagnostic subgroups, not investigated in pharma-led clinical studies, but their potential use on new indications is never explored due to limited number of patients. Methods In this national, investigator-initiated, prospective, open-label, non-randomized combined basket- and umbrella-trial, patients are enrolled in multiple parallel cohorts. Each cohort is defined by the patient’s tumour type, molecular profile of the tumour, and study drug. Treatment outcome in each cohort is monitored by using a Simon two-stage-like ‘admissible’ monitoring plan to identify evidence of clinical activity. All drugs available in IMPRESS-Norway have regulatory approval and are funded by pharmaceutical companies. Molecular diagnostics are funded by the public health care system.

• Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Frich, Jan C. & Thoresen, Steinar [Vis alle 13 forfattere av denne artikkelen] (2022). Arendalsuka 2022: Nøkkelen til bedre kreftbehandling er samarbeid. [Internet]. Arendalsuka, Paneldebatt. Fulltekst i vitenarkiv
• Tasken, Kjetil & Smeland, Sigbjørn (2022). Description of the Norwegian Precision Medicine Initiatives published in Nature Medicine. [Internet]. IMPRESS-Norway. Fulltekst i vitenarkiv
• Kværner, Ane Sørlie; Minaguchi, Jun; Yamani, Naouale El; Henriksen, Christine; Ræder, Hanna & Paur, Ingvild [Vis alle 12 forfattere av denne artikkelen] (2017). DNA damage in blood cells in relation to chemotherapy and nutritional status in colorectal cancer patients. Fulltekst i vitenarkiv
• Rangel-Huerta, Oscar Daniel; Paur, Ingvild; Bastani, Nasser Ezzatkhah; Bøhn, Siv Kjølsrud; Lilleby, Wolfgang & Smeland, Sigbjørn [Vis alle 8 forfattere av denne artikkelen] (2017). Association between amino acids, biomarkers of prostate cancer and inflammation in Norwegian prostate cancer patients. Fulltekst i vitenarkiv
• Ræder, Hanna; Henriksen, Christine; Bøhn, Siv Kjølsrud; Vilbo, Anne Rikke O`de Fey; Henriksen, Hege & Kværner, Ane Sørlie [Vis alle 9 forfattere av denne artikkelen] (2016). A high proportion of cachectic cancer patients are not identified by the Patient-Generated Subjective Global Assessment tool. Fulltekst i vitenarkiv
• Thorsen, Lene; Jagestad, Dennis; Nystad, Roy; Geirdal, Amy Østertun; Smeland, Sigbjørn & Dahl, Alv A (2014). Characteristics of cancer patients who had non-improved work status six months after an outpatient rehabilitation program. Fulltekst i vitenarkiv
• Høland, Maren; Kolberg, Mathias; Davidson, Ben; Hall, Kirsten Sundby; Mertens, Fredrik & Berg, E van den [Vis alle 10 forfattere av denne artikkelen] (2014). Genomic copy number changes and the prognostic impact of the encoded genes PTEN and BIRC5 in malignant peripheral nerve sheath tumours. European Journal of Cancer. ISSN 0959-8049. 50, s. 106–106. Fulltekst i vitenarkiv
• Guddal, Maren Hjelle; Dahl, Alv A; Nystad, Roy; Thorsen, Lene; Fossa, Sophie D. & Smeland, Sigbjørn (2013). Effects of a Brief Outpatient Rehabilitation Program for Cancer Patients on Physical Activity, Return to Work and Quality of Life. Psycho-Oncology. ISSN 1057-9249. 22, s. 289–290. Fulltekst i vitenarkiv
• Bielack, S.; Sorg, B.; Cesari, M.; Hall, Kirsten Sundby; Marchesi, E. & Kevric, M. [Vis alle 10 forfattere av denne artikkelen] (2013). Presentation, treatment, and prognosis of recurrent osteosarcoma: The EUropean RELapsed OsteoSarcoma Registry (EURELOS). European Journal of Cancer. ISSN 0959-8049. 49, s. S877–S877. Fulltekst i vitenarkiv
• Wilhelm, Michael; Zils, K.; Bielack, S.; Kevric, M.; Reichardt, Peter & Smeland, Sigbjørn [Vis alle 12 forfattere av denne artikkelen] (2012). Bone sarcoma in patients older than 40 years. Interim results of the European Bone Over 40 Sarcoma Study (EURO-BOSS) for patients with localized completely resected tumors. Onkologie (Basel). ISSN 0378-584X. 35, s. 170–170. Fulltekst i vitenarkiv
• Bielack, S.; Hook, Jennifer; Jovic, G.; Marina, N.; Reichardt, Peter & Smeland, Sigbjørn [Vis alle 11 forfattere av denne artikkelen] (2012). Lack of trial participation and lack of centralization for young adults with osteosarcoma: Experience from the European and American Osteosarcoma Study, EURAMOS-1. Onkologie (Basel). ISSN 0378-584X. 35, s. 250–250. Fulltekst i vitenarkiv
• Whelan, Jeremy; Hook, Jane; Bielack, Stefan S.; Marina, Neyssa; Smeland, Sigbjørn & Jovic, Gordana [Vis alle 17 forfattere av denne artikkelen] (2012). EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma. Journal of Clinical Oncology. ISSN 0732-183X. 30(15). Fulltekst i vitenarkiv
• Josefsen, Dag; Smeland, Sigbjørn; Dyrhaug, Marianne; Rusten, L. & Kvalheim, Gunnar (2011). Ex vivo expansion of megakaryocytic progenitor cells to alleviate thrombocytopenia following multiple cycles of high-dose chemotherapy for highly malignant sarcoma. Bone Marrow Transplantation. ISSN 0268-3369. 46, s. S333–S333. Fulltekst i vitenarkiv
• Zils, Katja; Marina, Neyssa; Bielack, Stefan; Jovic, Gordana; Pickering, James & Sydes, Matthew Robert [Vis alle 9 forfattere av denne artikkelen] (2011). LACK OF CENTRALIZATION AND UNDER-RECRUITING OF YOUNG-ADULTS: LESSONS FROM EURAMOS-1/AOST0331 (NCT00134030). Pediatric Blood & Cancer. ISSN 1545-5009. 57(5), s. 779–779. Fulltekst i vitenarkiv
• Karlsen, Anette; Lilleby, Wolfgang; Klein, Willibrord; Laake, Petter; Fosså, Sophie Dorothea & Eri, Lars Magne [Vis alle 9 forfattere av denne artikkelen] (2010). A phase I/II randomized controlled trial investigating the effects of two dietary intervention strategies in prostate cancer patients. Fulltekst i vitenarkiv
• Kolberg, Matthias; Ågesen, Trude Holmeide; Brekke, Helge Roar; Skotheim, Rolf Inge; Hall, Kirsten Sundby & Berg, Eva van den [Vis alle 10 forfattere av denne artikkelen] (2010). Prognostic value of gene expression targeted by gain of 17q sequences in malignant peripheral nerve sheath tumours. European Journal of Cancer. ISSN 0959-8049. 8(5), s. 32–32. Fulltekst i vitenarkiv
• Danielsen, Stine Aske; Lind, Guro Elisabeth; Hall, Kirsten Sundby; Smeland, Sigbjørn; Berg, E van den & Mertens, F. [Vis alle 8 forfattere av denne artikkelen] (2010). Epigenetic target genes in malignant peripheral nerve sheath tumours identified as surrogate prognostic biomarkers. European Journal of Cancer. ISSN 0959-8049. 8(5), s. 43–43. Fulltekst i vitenarkiv

Se alle arbeider i NVA